EverSource Wealth Advisors’s Acrivon Therapeutics ACRV Stock Holding History

EverSource Wealth Advisors’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-373	Closed	-$899	–	4384
2025 Q4	$899	Hold	373	–	–	﹤0.01%	3734
2025 Q3	$675	Buy	+373	New	+$524	﹤0.01%	3863

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EverSource Wealth Advisors's ACRV Position: Q1 2026 in Review

EverSource Wealth Advisors sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 373 shares — an estimated $899 sold.

EverSource Wealth Advisors first reported a position in ACRV in Q3 2025 and held it in 2 quarters. The position peaked at $899 in Q4 2025. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

EverSource Wealth Advisors reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
EverSource Wealth Advisors sold 373 Acrivon Therapeutics shares in Q1 2026, an estimated $899.
EverSource Wealth Advisors first reported a position in Acrivon Therapeutics in Q3 2025 and held it in 2 quarters.
EverSource Wealth Advisors's Acrivon Therapeutics position peaked at $899 in Q4 2025.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.